Pete Stavropoulos
Stock Analyst at Cantor Fitzgerald
(2.24)
# 2,601
Out of 5,182 analysts
53
Total ratings
29.73%
Success rate
3.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Pete Stavropoulos
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVO CervoMed | Initiates: Overweight | n/a | $3.98 | - | 1 | Dec 18, 2025 | |
| NVAX Novavax | Initiates: Overweight | $18 | $7.97 | +125.85% | 1 | Oct 24, 2025 | |
| ALEC Alector | Downgrades: Neutral | n/a | $2.35 | - | 6 | Oct 22, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Neutral | n/a | $0.68 | - | 5 | Jul 7, 2025 | |
| DRUG Bright Minds Biosciences | Assumes: Overweight | n/a | $74.98 | - | 1 | Jul 2, 2025 | |
| VERA Vera Therapeutics | Maintains: Overweight | $107 → $100 | $40.45 | +147.25% | 8 | May 7, 2025 | |
| VYGR Voyager Therapeutics | Reiterates: Overweight | n/a | $3.97 | - | 2 | Mar 12, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Reiterates: Overweight | n/a | $8.22 | - | 6 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Reinstates: Neutral | n/a | $1.31 | - | 5 | Mar 4, 2025 | |
| KALV KalVista Pharmaceuticals | Reiterates: Overweight | n/a | $20.19 | - | 1 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.80 | - | 9 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.48 | - | 1 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $85.50 | - | 1 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $3.26 | +53.37% | 3 | Sep 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $2.76 | +371.01% | 2 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $8 | $21.48 | -62.76% | 1 | Mar 20, 2023 |
CervoMed
Dec 18, 2025
Initiates: Overweight
Price Target: n/a
Current: $3.98
Upside: -
Novavax
Oct 24, 2025
Initiates: Overweight
Price Target: $18
Current: $7.97
Upside: +125.85%
Alector
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.35
Upside: -
Jasper Therapeutics
Jul 7, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.68
Upside: -
Bright Minds Biosciences
Jul 2, 2025
Assumes: Overweight
Price Target: n/a
Current: $74.98
Upside: -
Vera Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $107 → $100
Current: $40.45
Upside: +147.25%
Voyager Therapeutics
Mar 12, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.97
Upside: -
Arcturus Therapeutics Holdings
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $8.22
Upside: -
Pliant Therapeutics
Mar 4, 2025
Reinstates: Neutral
Price Target: n/a
Current: $1.31
Upside: -
KalVista Pharmaceuticals
Dec 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $20.19
Upside: -
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.80
Upside: -
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.48
Upside: -
Jun 27, 2024
Initiates: Overweight
Price Target: n/a
Current: $85.50
Upside: -
Sep 19, 2023
Reiterates: Overweight
Price Target: $5
Current: $3.26
Upside: +53.37%
Jul 17, 2023
Reiterates: Overweight
Price Target: $13
Current: $2.76
Upside: +371.01%
Mar 20, 2023
Reiterates: Overweight
Price Target: $8
Current: $21.48
Upside: -62.76%